The UF Health Cancer Center will be well-represented at the American Society of Hematology (ASH) 66th Annual Meeting & Exposition in San Diego from Dec. 7-10.
The ASH Annual Meeting is the most comprehensive hematology event of the year. The meeting will provide an invaluable educational experience and overview of the latest scientific highlights in hematology. ASH is a great opportunity for hematology/oncology researchers to engage with colleagues and network with more than 25,000 hematology professionals from every subspecialty.
View the full conference program.
UF Health Cancer Center members appear in bold. Cancer trainees appear in underline.
Plenary Scientific Session
Sunday, Dec. 8
1 Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
Coauthors include: John Kairalla, Ph.D., Cindy Wang, Susan Conway
Special Interest Sessions: ASH Quality Improvement Champions
Monday, Dec. 9
Optimized Management of Hemophilia in the Emergency Department
Asinamai M Ndai, BPharm, MS
University of Florida Health Physicians, Gainesville, FL
Oral Presentations
Saturday, Dec. 7
103 Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia
Presenter: Francisco Marchi, B.S.
Coauthors include: Ann-Kathrin Schade, Vivek M. Shastri, Ph.D., Jatinder Lamba, Ph.D.
224 Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
Coauthors include: Christopher R. Cogle, M.D.
315 Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
Coauthors include: John Kairalla, Ph.D.
Sunday, Dec. 8
680 Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies
Coauthors include: John Ligon, M.D.
Monday, Dec. 9
709 Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
Coauthors include: John Fort, M.D.
Poster Presentations
Saturday, Dec. 7
1968 Soluble B-Cell Maturation Antigen As a Serum Marker of Minimal Residual Disease in Patients with Multiple Myeloma
Presenter: Erin Dean, M.D.
Coauthors include: Derek M. Li, Tuo Lin, Ph.D., Robert P. Seifert, M.D., John W. Hiemenz, M.D., John R. Wingard, M.D.
1337 Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells
Presenter: Chunjie Yu, Ph.D.
Coauthors include: Qiong Qu, Ph.D., Fang Yu, Ph.D., Yue Sheng, Ph.D., Yafang Li, Ph.D., Yutao Zhang, Jue Wang, Ph.D., Zhigang Hou, Ph.D., Zhijian Qian, Ph.D.
1543 Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients
Presenter: Vivek Shastri, Ph.D.
Coauthors include: Francisco Marchi, Jatinder Lamba, Ph.D.
1394 Immunotherapeutic Potential and In Vivo Targeting of CD33 Splice Variant Isoform
Presenter: Vivek Shastri, Ph.D.
Coauthors include: Jatinder Lamba, Ph.D.
1282 A Senescent Subset in Human Hematopoietic Stem Cell (HSC) Compartment As Target for Senotherapy
Coauthors include: Bowen Yan, Ph.D.
2021 CCR2 Cooperatively Regulates Hematopoietic Stem Cell Homing to the Bone Marrow
Coauthors include: Jason Butler, Ph.D.
Sunday, Dec. 8
2846 GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma
Presenter: Vivek M. Shastri, PhD
Coauthors include: Jennifer Ahmed, Pharm.D., Eva Spin
2797 Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
Coauthors include: John Ligon, M.D., John Kairalla, Ph.D.
2813 Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
Coauthors include: John Kairalla, Ph.D.
2749 Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
Coauthors include: Guangrong Zheng, Ph.D.
2691 Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
Coauthors include: Paul Castillo, M.D.
2786 Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL
Coauthors include: Peiyi Zhang, Wanyi Hu, Guangrong Zheng, Ph.D.
3820 Defining and Developing a Curriculum for Systems-Based Hematology: A Qualitative Thematic Analysis of Expert Interviews
Coauthors include: Marc Stuart Zumberg, M.D.
2813 Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
Coauthors include: John A. Kairalla, Ph.D., Emily Hibbitts, Ph.D.
Monday, Dec. 9
4195 Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children’s Oncology Group Protocols AALL0932 and AALL1131
Coauthors include: John A. Kairalla, Ph.D., Emily Hibbitts, Ph.D.
4125 Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies
Coauthors include: Fang Yu, Ph.D., Zhijian Qian, Ph.D.
4057 Clonal Hematopoiesis Driven By Mutations in DNMT3A Promotes Metabolic Disease
Presenter: Bowen Yan, Ph.D.
Coauthors include: Qingchen Yuan, MBB, Prabhjot Kaur, Ph.D., Annalisse Mckee, M.S., Daniil Shabashvili, Ph.D., Olga A. Guryanova, M.D., Ph.D.
4327 Genome-Wide Association Study of Metabolites in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia Identified Novel Metabolite Quantitative Trait Loci
Presenter: Richard J Marrero, Pharm.D.
Coauthors include: Jatinder Lamba, Ph.D.
4663 Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
Coauthors include: Jonathan D. Licht, M.D.
5019 Development of a Working Definition of Severe Von Willebrand Disease
Coauthors include: Tung Wynn, M.D.
4270 Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia
Coauthors include: Jatinder Lamba, Ph.D.
